Compare ADMA Biologics Inc (ADMA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Toronto-Dominion Bank — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Toronto-Dominion Bank trades at $118.72 (market cap $200.57B). The key difference: Toronto-Dominion Bank is far larger — about 94.2× ADMA Biologics Inc's market cap, and Toronto-Dominion Bank pays a 2.67% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TD | |
|---|---|---|
Market Cap | $2.13B | $200.57B |
Sector | Health | Financials |
52-Week High | $20.38 | $122.25 |
52-Week Low | $7.60 | $72.55 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TD stock trades at $121.43, up 1.79% today, with a bullish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. Analysts maintain a buy consensus with a $153 price target, and the company recently increased its dividend.
The outlook is positive given strong profitability, dividend growth, and analyst support, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers value with a P/E of 20.1 and robust ROE of 12.59%, though investors should monitor credit performance amid economic softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
